Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly.
The safety and immunogenicity of purified fusion protein (PFP-2) respiratory syncytial virus (RSV) vaccine was evaluated in an open label study in 37 frail institutionalized persons over age 65. Vaccination was well tolerated without significant side-effects. Thirty-six of 37 volunteers completed the study. Nineteen of 36 (53%) vaccinees had a greater than or equal to fourfold increase in IgG to F protein at 4 weeks and 17 (47%) had a greater than or equal to fourfold rise in neutralizing titers to either group A or B virus. Although response rate to PFP-2 vaccine in the frail elderly was somewhat diminished compared to results in the healthy elderly, the vaccine was well tolerated and relatively immunogenic.
Falsey
A R
AR
University of Rochester School of Medicine and Dentistry, NY, USA.
Walsh
E E
EE
D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D002908:Chronic Disease; D005260:Female; D006707:Homes for the Aged; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D009500:Neutralization Tests; D009735:Nursing Homes; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology*; D012141:Respiratory Tract Infections / Q000276:immunology / Q000517:prevention & control*; D012449:Safety; D014614:Vaccines, Synthetic / Q000494:pharmacology*; D014760:Viral Fusion Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects / Q000494:pharmacology*
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D014614:Vaccines, Synthetic; D014760:Viral Fusion Proteins; D014765:Viral Vaccines